ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,751,620 | -11.7% | 433,000 | 0.0% | 11.84% | -18.2% |
| Q2 2023 | $13,310,420 | -14.7% | 433,000 | 0.0% | 14.48% | -20.5% |
| Q1 2023 | $15,600,990 | -14.6% | 433,000 | -6.3% | 18.22% | -8.9% |
| Q4 2022 | $18,258,240 | -12.9% | 462,000 | -11.5% | 20.01% | -6.9% |
| Q3 2022 | $20,964,000 | -12.8% | 521,750 | -8.7% | 21.48% | +1.3% |
| Q2 2022 | $24,030,000 | -18.5% | 571,588 | -24.5% | 21.21% | -4.2% |
| Q1 2022 | $29,488,000 | -8.2% | 756,874 | -6.1% | 22.15% | -5.0% |
| Q4 2021 | $32,118,000 | +26.7% | 805,982 | +14.9% | 23.31% | +13.6% |
| Q3 2021 | $25,346,000 | -13.1% | 701,323 | -1.4% | 20.53% | -13.2% |
| Q2 2021 | $29,169,000 | +4073.0% | 711,623 | +4341.3% | 23.64% | +2870.4% |
| Q1 2021 | $699,000 | -29.2% | 16,023 | -18.7% | 0.80% | -30.7% |
| Q4 2020 | $987,000 | +0.7% | 19,718 | -15.3% | 1.15% | -6.4% |
| Q3 2020 | $980,000 | +129.5% | 23,288 | +149.7% | 1.23% | +129.1% |
| Q2 2020 | $427,000 | – | 9,328 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |